FDA Approves Circassia’s COPD Combination Product

The FDA has granted approval for Circassia’s chronic obstructive pulmonary disease (COPD) combination product, which uses the Pressair multi-dose inhaler.

The inhaler is preloaded with the dry powder Duaklir (aclidinium bromide/formoterol 400µg/12µg twice-daily) upon breath activation. The treatment relaxes the patient’s airway muscles, helping to keep them open and assisting the patient in breathing more easily.

Circassia said it plans to launch the product on the U.S. market in the coming months.